Previous 10 | Next 10 |
2023-07-27 18:56:08 ET Biotech stocks are famously volatile, and investors needed to look no further than the performance of Novocure 's (NASDAQ: NVCR) shares on Thursday for proof. The company's share price cratered by almost 16% on the day due to worse-than-expected fundamentals f...
2023-07-27 11:30:26 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2023 Earnings Call Jul 27, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2023 Earnings Call Transcript
2023-07-27 07:11:47 ET NovoCure press release ( NASDAQ: NVCR ): Q2 GAAP EPS of -$0.54 misses by $0.04 . Revenue of $126.05M (-10.5% Y/Y) beats by $1.8M . 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer ...
Quarterly net revenues of $126 million with 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four phase 3 trials to readout by year-end 2024 Interim analysis for fu...
2023-07-26 12:27:10 ET NovoCure ( NASDAQ: NVCR ) is scheduled to announce Q2 earnings results on Thursday, July 27th, before market open. The consensus EPS Estimate is -$0.50 and the consensus Revenue Estimate is $124.25M (-11.8% Y/Y). Over the last 2 years, NVCR has...
2023-07-25 17:09:58 ET Summary In early June, NovoCure's stock dropped 43% in a single day after the company presented the LUNAR study at ASCO. The stock now trades near 5-year lows. What caused the drop exactly? And is this the end of the story for NovoCure? The details of th...
New York, New York--(Newsfile Corp. - July 25, 2023) - Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: NovoCure Limited (NASDAQ: NVCR) NovoCure is a global oncology company with a proprietary platform technology c...
2023-07-22 05:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Economic resiliency, s...
Pre-specified interim analysis concluded that the fully enrolled PANOVA-3 clinical trial should proceed to final analysis as planned Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and ...
MOORE KUEHN ANNOUNCES ENCOURAGES NOVOCURE LIMITED INVESTORS TO CONTACT LAW FIRM PR Newswire NEW YORK , July 14, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: ...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...